Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 69.65M.
Subavaliada
O PE mais recente da empresa é -13.53, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 65.32M ações, um aumento de 2.84% em relação ao trimestre anterior.
Mantido por Catherine Wood
O Super Investidor Catherine Wood possui 5.33M ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 1.43.